Statins Do Not Affect Bone Anabolism in Older Women Treated With Teriparatide
Authors' conclusion
Statin use does not impair the anabolic efficacy of rhPTH in increasing BMD in postmenopausal women with severe osteoporosis, but it provides additional antiresorptive benefits during rhPTH therapy. These findings support the continued use of statins and highlight the need for further prospective studies exploring synergistic effects.
Study context
- Population
- Postmenopausal women with severe osteoporosis who completed 24 months of daily rhPTH (20 mcg SC) and biweekly cholecalciferol (25,000 IU)
- Participants
- 104 women
- Exposure
- Statin users vs nonusers during teriparatide therapy
- Statin usersn = 30
- Nonusersn = 74reference
- Outcome
- Changes in BMD (lumbar spine, femoral neck) and bone turnover markers
- Follow-up
- 24 months
Main finding
As reported in the abstract
- Statin users: lumbar spine bone mineral density (BMD) from 0.71 ± 0.16 to 0.79 ± 0.14 g/cm²
- P = .01
- Nonusers: lumbar spine BMD from 0.70 ± 0.10 to 0.77 ± 0.11 g/cm²
- P = .001
Observational data: associations, not effects.
Further findings
C-terminal telopeptide of type I collagen · end of observation period · significantly lower in statin users
P = 0.007
Femoral neck BMD, baseline to completion · 24 months
- Statin users: trend toward improvement from 0.53 ± 0.24 to 0.62 ± 0.12 g/cm²
- P = 0.07
- Nonusers: no significant change from 0.60 ± 0.11 to 0.58 ± 0.15 g/cm²
- P = 0.5
Alkaline phosphatase and osteocalcin · throughout observation period
- No significant intergroup differences
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →